Perspective Therapeutics 관리

관리 기준 확인 1/4

Perspective Therapeutics CEO는 Thijs Spoor, Feb2023 에 임명되었습니다 의 임기는 1.75 년입니다. 총 연간 보상은 $ 1.46M, 34.7% 로 구성됩니다. 34.7% 급여 및 65.3% 보너스(회사 주식 및 옵션 포함). 는 € 237.21K 가치에 해당하는 회사 주식의 0.031% 직접 소유합니다. 237.21K. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 1.8 년입니다.

주요 정보

Thijs Spoor

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	34.7%
CEO 임기	1.8yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	1.7yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Thijs Spoor 의 보수는 Perspective Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

보상 대 시장: Thijs 의 총 보상 ($USD 1.46M )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.42M ).

보상과 수익: Thijs 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Thijs Spoor (52 yo)

1.8yrs

테뉴어

US$1,458,996

보상

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Johan Spoor	CEO & Director	1.8yrs	US$1.46m	0.031% € 237.2k
Jonathan Hunt	CFO and Principal Financial & Accounting Officer	5.9yrs	US$1.17m	0.053% € 411.1k
Markus Puhlmann	Chief Medical Officer	1.8yrs	US$900.09k	0.20% € 1.6m
Shane Cobb	Executive Vice President of Operations	1.3yrs	데이터 없음	데이터 없음
Michael Schultz	Chief Science Officer	no data	데이터 없음	2.2% € 17.0m
Annie Cheng	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Andrew Bright	Executive Vice President of Brachytherapy	1.6yrs	데이터 없음	데이터 없음
Amos Hedt	Chief Business Strategy Officer	no data	데이터 없음	데이터 없음
Frances Johnson	Chief Innovation Officer	no data	데이터 없음	2.2% € 17.0m
David Hauser	Senior Vice President of Clinical Operations	no data	데이터 없음	데이터 없음
Steve Keefe	Senior Vice President of Clinical Development	less than a year	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: AAJ0 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Johan Spoor	CEO & Director	1.8yrs	US$1.46m	0.031% € 237.2k
Robert Williamson	Independent Director	1.8yrs	US$320.06k	0.063% € 488.6k
Frank Morich	Independent Director	1.8yrs	US$320.06k	데이터 없음
Heidi Henson	Independent Director	1.4yrs	US$390.70k	데이터 없음
Lori Holmes-Woods	Chairperson of the Board	6.4yrs	US$671.73k	0.24% € 1.9m

1.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: AAJ0 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Perspective Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new and inexperienced directors

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought €128k worth of stock

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

Perspective Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma Research

High number of new and inexperienced directors

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings released: US$0.024 loss per share (vs US$0.002 loss in 1Q 2023)

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Revenue size

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought €128k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.029 loss in 3Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.015 loss in 2Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.011 loss in 2Q 2022)

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings released: US$0.029 loss per share (vs US$0.016 loss in 1Q 2022)

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings released: US$0.051 loss per share (vs US$0.033 loss in FY 2021)

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령